| 13.22 -0.29 (-2.15%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 16.34  |
1-year : | 16.93 |
| Resists | First : | 13.99 |
Second : | 14.5 |
| Pivot price | 13.93 |
|||
| Supports | First : | 13.18 |
Second : | 10.96 |
| MAs | MA(5) : | 13.48 |
MA(20) : | 13.97 |
| MA(100) : | 14.57 |
MA(250) : | 14.34 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8  |
D(3) : | 6.2 |
| RSI | RSI(14): 24.1 |
|||
| 52-week | High : | 16.67 | Low : | 12.72 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ INMD ] has closed below the lower bollinger band by 0.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 55.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 13.64 - 13.71 | 13.71 - 13.78 |
| Low: | 12.95 - 13.05 | 13.05 - 13.14 |
| Close: | 13.06 - 13.22 | 13.22 - 13.35 |
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
Thu, 29 Oct 2026
InMode Ltd. (INMD) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada
Fri, 16 Oct 2026
InMode Ltd. (INMD) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Wed, 27 May 2026
Inmode Ltd (INMD) Reports Solid Numbers in a Soft Market - Yahoo Finance
Fri, 09 Jan 2026
InMode Ltd. (INMD) Stock Price: Oct 29 Close $13.51 - Gotrade
Wed, 27 Aug 2025
InMode Ltd. (INMD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Thu, 05 Jun 2025
Inmode Ltd (INMD): Is This Deeply Undervalued Stock a Hidden Gem? - The Acquirer's Multiple
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 58 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 13.1 (%) |
| Held by Institutions | 55.9 (%) |
| Shares Short | 2,250 (K) |
| Shares Short P.Month | 2,350 (K) |
| EPS | 1.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.68 |
| Profit Margin | 20.6 % |
| Operating Margin | 12.8 % |
| Return on Assets (ttm) | 6.1 % |
| Return on Equity (ttm) | 12.3 % |
| Qtrly Rev. Growth | -0 % |
| Gross Profit (p.s.) | 4.98 |
| Sales Per Share | 6.51 |
| EBITDA (p.s.) | 1.23 |
| Qtrly Earnings Growth | -31 % |
| Operating Cash Flow | 84 (M) |
| Levered Free Cash Flow | 47 (M) |
| PE Ratio | 10.92 |
| PEG Ratio | 0.8 |
| Price to Book value | 1.23 |
| Price to Sales | 2.03 |
| Price to Cash Flow | 9.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|